X
Xin Lu
Publications - 7
Citations - 707
Xin Lu is an academic researcher. The author has contributed to research in topics: Dupilumab & Nasal polyps. The author has an hindex of 2, co-authored 6 publications receiving 329 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert,Claus Bachert,Joseph K. Han,Martin Desrosiers,Peter Hellings,Nikhil Amin,Stella E. Lee,Joaquim Mullol,Leon S. Greos,John V. Bosso,Tanya M. Laidlaw,Anders Cervin,Jorge Maspero,Claire Hopkins,Heidi Olze,G. Walter Canonica,Pierluigi Paggiaro,Seong H. Cho,Wytske Fokkens,Shigeharu Fujieda,M. Zhang,Xin Lu,Chunpeng Fan,Steven Draikiwicz,Siddhesh Kamat,Asif Khan,Gianluca Pirozzi,Naimish Patel,Neil M.H. Graham,Marcella Ruddy,Heribert Staudinger,David M. Weinreich,Neil Stahl,George D. Yancopoulos,Leda Mannent +34 more
TL;DR: Dupilumab significantly improved the coprimary endpoints in both studies and was added to standard of care in adults with severe CRSwNP despite previous treatment with systemic corticosteroids, surgery, or both.
Journal ArticleDOI
A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps
Claus Bachert,Martin Desrosiers,Joaquim Mullol,Peter Hellings,Anders Cervin,Lawrence Sher,John V. Bosso,Stella E. Lee,Jorge Maspero,Shigeharu Fujieda,Shoji Matsune,Xin Lu,Chunpeng Fan,Steven Draikiwicz,Nikhil Amin,Siddhesh Kamat,Asif Khan,Gianluca Pirozzi,Neil M.H. Graham,Marcella Ruddy,Heribert Staudinger,Leda Mannent +21 more
TL;DR: In a phase 2a study, dupilumab improved endoscopic, radiologic, clinical, and patient-reported outcomes in chronic rhinosinusitis with nasal polyps patients in patients aged >_12 years with moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.
Journal ArticleDOI
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Surya P. Bhatt,Klaus F. Rabe,Nicola A. Hanania,Claus Vogelmeier,J. Cole,Mona Bafadhel,Stephanie A. Christenson,Alberto Papi,Dave Singh,Elizabeth Laws,Leda Mannent,Naimish Patel,Heribert Staudinger,George D. Yancopoulos,Eric Mortensen,Bolanle Akinlade,J. Maloney,Xin Lu,Deborah Bauer,Ashish Bansal,Lacey B. Robinson,Raolat M. Abdulai +21 more
TL;DR: In this paper , a double-blind, randomized trial was conducted where patients with COPD who had elevated blood eosinophil counts were assigned to receive dupilumab (300 mg) or placebo subcutaneously once every 2 weeks.
Proceedings ArticleDOI
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials
Tanya M. Laidlaw,Joaquim Mullol,G. Walter Canonica,Claus Bachert,Joseph K. Han,M. Zhang,Xin Lu,Naimish Patel,Neil M.H. Graham,Heribert Staudinger,Leda Mannent,Nikhil Amin +11 more
Proceedings ArticleDOI
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials
Joaquim Mullol,Tanya M. Laidlaw,Nikhil Amin,Claus Bachert,Joseph K. Han,Peter Hellings,G. Walter Canonica,Seong H. Cho,Jorge Maspero,Martin Desrosiers,Claire Hopkins,Pierluigi Paggiaro,M. Zhang,Xin Lu,Naimish Patel,Neil M.H. Graham,Heribert Staudinger,Leda Mannent +17 more
TL;DR: DPL improved endoscopic, clinical, radiologic and pt-reported outcomes similarly in CRSwNP pts with/without NASID-ERD and was well tolerated.